Cargando…

Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom

INTRODUCTION: It is unclear as to whether human or long-acting analog insulins represent the most efficient use of health and non-healthcare resources in the management of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the value for money relationship associated with the use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Jason, Evans, Marc, McEwan, Phil, Bain, Steve, Vora, Jiten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687091/ https://www.ncbi.nlm.nih.gov/pubmed/23296753 http://dx.doi.org/10.1007/s13300-012-0018-3

Ejemplares similares

Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
por: Vora, Jiten, et al.
Publicado: (2014)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

Combining Incretin-Based Therapies With Insulin: Realizing the potential in type 2 diabetes
por: Vora, Jiten
Publicado: (2013)

Emerging role of insulin with incretin therapies for management of type 2 diabetes
por: Ahluwalia, Rupa, et al.
Publicado: (2011)

Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study
por: Gordon, Jason, et al.
Publicado: (2018)

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes
por: Gordon, Jason, et al.
Publicado: (2017)

Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
por: Bennett, Hayley, et al.
Publicado: (2014)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
por: Linde, Cecilia, et al.
Publicado: (2019)

One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2021)

A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
por: Evans, Marc, et al.
Publicado: (2012)

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy
por: Gordon, Jason P., et al.
Publicado: (2015)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
por: McEwan, Phil, et al.
Publicado: (2016)

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
por: Sharplin, Peter, et al.
Publicado: (2009)

Value for Money
Publicado: (1920)

Trends in licence approvals for ophthalmic medicines in the United Kingdom
por: Morgan-Warren, Peter J., et al.
Publicado: (2020)

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study
por: Gordon, J, et al.
Publicado: (2010)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study
por: Damci, Taner, et al.
Publicado: (2014)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

Best value for money
por: CERN Bulletin
Publicado: (2011)

The Money-Value Again
Publicado: (1892)

What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
por: Strain, W. David, et al.
Publicado: (2020)

Evaluating insulin information provided on discharge summaries in a secondary care hospital in the United Kingdom
por: Bain, Amie, et al.
Publicado: (2017)

Money Value of Medical Attendance
Publicado: (1892)

Best Value for Money in Triptans
por: Curtiss, Frederic R.
Publicado: (2005)

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease
por: Evans, Marc, et al.
Publicado: (2019)

Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA(1c), weight and hypoglycaemic event incidence
por: McEwan, P., et al.
Publicado: (2018)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan
por: Matsumoto, Tetsuya, et al.
Publicado: (2021)

Assessment of Insulin-related Knowledge among Healthcare Professionals in a Large Teaching Hospital in the United Kingdom
por: Bain, Amie, et al.
Publicado: (2019)

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
por: Giorgino, Francesco, et al.
Publicado: (2020)

Antimicrobial resistance and characterisation of staphylococci isolated from healthy Labrador retrievers in the United Kingdom
por: Schmidt, Vanessa M, et al.
Publicado: (2014)

Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?
por: Giorgino, Francesco, et al.
Publicado: (2020)

Was attending the conference worth value for money?
por: Bhattacharya, Surajit
Publicado: (2014)

Audit Reviewed: Value for Money in Medicine
por: Hoff, W. Van't
Publicado: (1983)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
por: Davies, Melanie, et al.
Publicado: (2013)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes
por: Ritzel, Robert, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_895u67fu3lrjg257q5f4j72lk0